Search alternatives:
point decrease » point increase (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e point » _ point (Expand Search), 5 point (Expand Search), a point (Expand Search)
point decrease » point increase (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e point » _ point (Expand Search), 5 point (Expand Search), a point (Expand Search)
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
Fenretinide decreases levels of PAX3/FOXO1 and its target genes in aRMS cell lines.
Published 2013“…D) Fenretinide did not decrease mRNA levels of FOXO1 in aRMS cells. qRT–PCR was carried out after treatment with an IC<sub>50</sub> concentration of fenretinide during different time points (24–48–72 hours). …”
-
130
-
131
-
132
Decrease in cell viability by siRNA and miRNA dependent induction of DTA.
Published 2014“…<p>U251 cells were transfected with the indicated construct (50 ng) with (A) or without (B) siRNAs (10pmol). …”
-
133
-
134
-
135
The 5’SS motif decreases mRNA stability and promotes nuclear retention.
Published 2015“…Note that the relative level of <i>c-ftz-Δi-V5-His</i> decreases over the first 60 min until 40–50% of the mRNA remains, after which point the ratio is stable. …”
-
136
-
137
Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.
Published 2016“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
-
138
-
139
-
140